Obesity is generally associated with a worse prostate cancer prognosis among men whose tumors contain TMPRSS2-ERG, a hormonally regulated gene fusion which leads to the over-expression of a truncated ERG protein, is present in about half of all prostate tumors. This is the conclusion reached by researchers from Harvard School of Public Health (HSPH), Dana-Farber Cancer Institute and Brigham and Women's Hospital researchers.
The study shows that…Continue
Added by Editorial Team on December 2, 2013 at 6:00pm — No Comments
According to results from a recent study published in the November 27, 2013 online edition of Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research, women who are members of families with BRCA2 mutations but who test negative for the family-specific BRCA2 mutations are still at greater risk for developing breast cancer compared with women in the general population.
Women with certain mutations in their BRCA1 or BRCA2…Continue
Added by Editorial Team on November 27, 2013 at 3:30pm — No Comments
A minimally invasive endoscopic procedure to remove superficial, early stage esophageal cancer is as effective as surgery that takes out and rebuilds the esophagus, according to a study by researchers at Mayo Clinic in Florida, USA, The research, published in the November issue of Clinical Gastroenterology and Hepatology, examined national outcomes from endoscopic treatment compared to esophagectomy, surgical removal of the esophagus.
It found that endoscopic therapy offered…Continue
Added by Editorial Team on November 7, 2013 at 2:00pm — No Comments
A multitude of medical studies have shown that a woman’s risk of developing breast cancer is directly related to her exposure to endogenous estrogen and progesterone, hormones that are produced by her ovaries. These ovarian hormones stimulate cell growth. Reproductive factors that increase the duration and/or levels of exposure to these hormones, include early onset of menstruation, late onset of menopause, later age at first pregnancy, and never having given birth have been associated…Continue
Added by Editorial Team on October 1, 2013 at 12:00pm — No Comments
A pilot study has shown large variations between European countries in patient survival after surgery for esophageal and gastric cancers. The data presented by Dutch researchers at the 2013 European Cancer Congress (ECC2013) shows that the reasons for these differences are not clear and cannot be explained simply in terms of the volume of patients treated at each hospital.…Continue
Added by Editorial Team on October 1, 2013 at 9:00am — No Comments
While much progress has been made in the "war" against cancer, a new report, presented at the 2013 European Cancer Congress (ECCO 2013) being held in Amsterdam, The Netherlands, September 27 - October 1, 2013, shows that not every cancer patient has the opportunity to benefit from the progress made in prevention, diagnosis, treatment.
"The economics of cancer are daunting and the current model of financing is broken," noted Professor Peter Boyle, Ph.D, President of the…Continue
Added by Editorial Team on September 30, 2013 at 9:30pm — No Comments
Patients diagnosed with early breast cancer may benefit from radiation therapy to the lymph nodes located behind the breast bone and above the collar bone. New finding show that this approach improves overall survival without increasing unwanted side effects. The study results, presented at the 2013 European Cancer Congress (ECC2013) being held in Amsterdam, The Netherlands, September 27 - October 1, 2013, also ends the uncertainty about whether the beneficial effect of radiation therapy…Continue
Added by Editorial Team on September 28, 2013 at 9:00pm — No Comments
A secondary analysis of the historic RTOG 92-02 prostate cancer trial examined results of men with intermediate-risk prostate cancer who had received long-term hormonal therapy after radiation therapy. Based on the additional analysis, researchers concluded that there were no additional benefits of this treatment when compared to short-term hormonal therapy. The study results were presented today at the American Society for Radiation…Continue
Added by Editorial Team on September 23, 2013 at 2:30pm — No Comments
For more than a century scientists have been searching for noninvasive technologies to peer deep inside the human body by using light. With much interests, healthcare professionals involved in the management of patients with cancer, want to see inside the body because they are interested in understanding the numerous subtle and often invisible changes to the human DNA, proteins, cells, and tissue involved in altering the body's normal biology.
For the first time, a team of…Continue
Added by Peter Hofland, PhD on September 17, 2013 at 2:00pm — No Comments
Natural Killer (NK) cells, a component of our innate immune system, are a type of lymphocyte designed to play a major role in defending our bodies in the host-rejection of both virally infected cells and cancer cells, thus protecting our bodies from harm.
Now, for the first time, scientists at Vetmeduni, the University of Veterinary Medicine, Vienna, Austria, show that NK-cell activity can be influenced by…Continue
Ductal carcinoma in situ or DCIS, a precursor of breast cancer, usually found during a mammogram as part of breast cancer screening, is the presence of abnormal cells inside a milk duct in the breast. While noninvasive and not life-threatening, it may progress to invasive breast cancer if left untreated and therefor requires treatment.…Continue
Added by Peter Hofland, PhD on September 5, 2013 at 12:30pm — No Comments
Results of a study by scientists at Johns Hopkins which was funded by the National Cancer Institute, identify a molecular marker called mitogen-inducible gene 6 or Mig6, a negative regulator of EGFR through the upregulation of the PI3K-AKT pathway. This molecular marker appears to accurately predict longer survival among patients prescribed two of the most widely used drugs in a class of anticancer agents called EGFR-inhibitors. These preliminary results need further…Continue
Added by Peter Hofland, PhD on September 5, 2013 at 10:00am — No Comments
The immune system is a collection of reactions and responses protecting our bodies from harm of infection and illness caused by bacteria, viruses, fungi or parasites. The body's primary in-built protection, the
innate immunity, is always ready and prepared to act immediately. A second mechanism, the acquired immunity, learns from being exposed to diseases and creates an immune memory for future defense. These 'good' systems keep us healthy.
But a new…Continue
Added by Peter Hofland, PhD on September 5, 2013 at 9:00am — No Comments
Scientists from the Florida campus of The Scripps Research Institute (TSRI), one of the world's largest independent, not-for-profit organizations focusing on research in the biomedical sciences, have shown that a well-known cancer-causing gene, Notch 1, implicated in a number of malignancies plays a far more critical role in non-small cell lung cancer (NSCLC), the most common form of the disease, than previously thought.
The Notch signaling network is an intercellular…Continue
Added by Editorial Team on August 29, 2013 at 8:00am — No Comments
According to researchers at Duke-NUS Graduate Medical School in Singapore, stomach or gastric cancer is a heterogeneous disease which falls into three broad subtypes with distinct biological properties and effects that respond differently to currently available therapies.
Understanding these research findings may help improve patient care. The researchers expect that the development of a genetic test designed to…Continue
Added by Editorial Team on August 27, 2013 at 4:00pm — No Comments
The recently completed SQUIRE study, a randomized, multicenter, open-label phase III study of gemcitabine-cisplatin chemotherapy plus necitumumab (IMC-11F8; Eli Lilly & Co/ImClone) versus gemcitabine-cisplatin chemotherapy alone in the first-line treatment of patients with stage IV squamous non-small cell lung cancer (NSCLC) met its primary endpoint. The study result showed…Continue
Added by Editorial Team on August 13, 2013 at 5:30pm — No Comments
Early full-term pregnancy is one of the most effective natural protections against breast cancer. Now, for the first time, an international scientific collaborative led by the Harvard Stem Cell Institute’s Kornelia Polyak, MD, PhD, has discovered why women who give birth in their early twenties are less likely to eventually develop breast cancer than women who don't, triggering a search for a way to confer this protective state on all women.
The researchers now are in the…Continue
Added by Editorial Team on August 12, 2013 at 3:30pm — No Comments
The treatment of patients with advanced prostate cancer remains challenging. Researchers from the Cincinnati Children's Hospital Medical Center, found that expression of the Forkhead box protein M1 or FoxM1 protein is up-regulated in prostate adenocarcinomas and its expression correlates with the poor prognosis.
FoxM1 is found in a variety of distinct human cancers including…Continue
Added by Editorial Team on August 1, 2013 at 7:30pm — No Comments
Data presented at the 18th Annual Congress of the European Hematology Association (EHA) being held in Stockholm, Sweden, June 13 - 16, 2013, of two separate Phase II studies suggest that ibrutinib (PCI-32765), an investigational oral Bruton's tyrosine kinase (BTK) inhibitor, shows efficacy when used as a monotherapy in patients with relapsed/refractory mantle cell lymphoma (MCL) or diffuse large B-cell lymphoma (DLBCL).…Continue
Added by Editorial Team on June 16, 2013 at 6:00pm — No Comments
The German phase III clinical trial FIRE-3 reports that first-line cetuximab (Erbitux®, Merck KGaA) plus FOLFIRI chemotherapy (folinic acid, fluorouracil, irinotecan) offers a roughly four-month survival advantage for patients with metastatic colorectal cancer, compared with bevacizumab (Avastin®, Genentech/Roche) plus FOLFIRI. The targeted drugs cetuximab and bevacizumab, both in combination with…Continue
Added by Editorial Team on June 1, 2013 at 3:30pm — No Comments